Back to top

Image: Bigstock

Epizyme (EPZM) Is Up 6.9% in One Week: What You Should Know

Read MoreHide Full Article

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.

Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.

Below, we take a look at Epizyme (EPZM - Free Report) , which currently has a Momentum Style Score of A. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Epizyme currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.

You can see the current list of Zacks #1 Rank Stocks here >>>

Set to Beat the Market?

Let's discuss some of the components of the Momentum Style Score for EPZM that show why this biopharmaceutical company shows promise as a solid momentum pick.

Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.

For EPZM, shares are up 6.9% over the past week while the Zacks Medical - Biomedical and Genetics industry is up 1.28% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 43.86% compares favorably with the industry's 4.84% performance as well.

While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Shares of Epizyme have increased 32.51% over the past quarter, and have gained 117.1% in the last year. On the other hand, the S&P 500 has only moved 10.46% and 19.76%, respectively.

Investors should also pay attention to EPZM's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. EPZM is currently averaging 776,805 shares for the last 20 days.

Earnings Outlook

The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with EPZM.

Over the past two months, 6 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost EPZM's consensus estimate, increasing from -$2.22 to -$1.89 in the past 60 days. Looking at the next fiscal year, 5 estimates have moved upwards while there have been 1 downward revision in the same time period.

Bottom Line

Taking into account all of these elements, it should come as no surprise that EPZM is a #2 (Buy) stock with a Momentum Score of A. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Epizyme on your short list.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Epizyme, Inc. (EPZM) - free report >>

Published in